Furthermore, resistance to paclitaxel in cancer cells occurs through the activation of efflux drug proteins, modification of molecular pathways involved in apoptosis, and upregulation of paclitaxel resistance-associated gene-3 (TRAG-3/CSAG2) expression [13]. Here, CSAG2 is linked to cancer.